JP2011518170A5 - - Google Patents

Download PDF

Info

Publication number
JP2011518170A5
JP2011518170A5 JP2011505132A JP2011505132A JP2011518170A5 JP 2011518170 A5 JP2011518170 A5 JP 2011518170A5 JP 2011505132 A JP2011505132 A JP 2011505132A JP 2011505132 A JP2011505132 A JP 2011505132A JP 2011518170 A5 JP2011518170 A5 JP 2011518170A5
Authority
JP
Japan
Prior art keywords
dotap
cationic lipid
enantiomer
agent
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011505132A
Other languages
English (en)
Japanese (ja)
Other versions
JP5971945B2 (ja
JP2011518170A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/040500 external-priority patent/WO2009129227A1/en
Publication of JP2011518170A publication Critical patent/JP2011518170A/ja
Publication of JP2011518170A5 publication Critical patent/JP2011518170A5/ja
Application granted granted Critical
Publication of JP5971945B2 publication Critical patent/JP5971945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011505132A 2008-04-17 2009-04-14 カチオン性脂質の鏡像異性体による免疫応答の刺激 Active JP5971945B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4583708P 2008-04-17 2008-04-17
US61/045,837 2008-04-17
PCT/US2009/040500 WO2009129227A1 (en) 2008-04-17 2009-04-14 Stimulation of an immune response by enantiomers of cationic lipids

Publications (3)

Publication Number Publication Date
JP2011518170A JP2011518170A (ja) 2011-06-23
JP2011518170A5 true JP2011518170A5 (enExample) 2013-05-23
JP5971945B2 JP5971945B2 (ja) 2016-08-17

Family

ID=41199446

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011505132A Active JP5971945B2 (ja) 2008-04-17 2009-04-14 カチオン性脂質の鏡像異性体による免疫応答の刺激

Country Status (13)

Country Link
US (4) US9789129B2 (enExample)
EP (1) EP2276495B1 (enExample)
JP (1) JP5971945B2 (enExample)
CN (2) CN102137675A (enExample)
AU (1) AU2009236306B2 (enExample)
BR (1) BRPI0910464B1 (enExample)
CA (1) CA2721366C (enExample)
ES (1) ES2712505T3 (enExample)
IL (1) IL208713A (enExample)
PL (1) PL2276495T3 (enExample)
RU (1) RU2530555C2 (enExample)
TW (1) TWI449534B (enExample)
WO (1) WO2009129227A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2011109294A1 (en) * 2010-03-01 2011-09-09 Dicerna Pharmaceuticals, Inc. Lipid delivery formulations
JP2011184344A (ja) * 2010-03-08 2011-09-22 Kao Corp ｐ２１発現促進剤
NZ606591A (en) 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
HRP20250981T1 (hr) 2011-05-24 2025-10-24 BioNTech SE Individualizirana cjepiva protiv raka
EP3456316A1 (en) 2011-07-06 2019-03-20 GlaxoSmithKline Biologicals S.A. Cationic oil-in-water emulsions
CN103781470A (zh) 2011-07-06 2014-05-07 诺华股份有限公司 包含核酸的水包油乳液
ES2689799T3 (es) * 2011-09-12 2018-11-15 Pds Biotechnology Corporation Formulaciones de vacunas particuladas
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
AU2013274235B2 (en) * 2012-06-15 2018-01-18 Samir N. Khleif Cationic lipid vaccine compositions and methods of use
AU2013317805B2 (en) * 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
AU2014365888B2 (en) * 2013-12-16 2018-12-06 Merck Patent Gmbh Survivin-directed cancer vaccine therapy
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP2019500021A (ja) * 2015-11-13 2019-01-10 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 樹状細胞療法においてｅｘ ｖｉｖｏでの抗原のプロセシングと提示を亢進させるための合成ベクターとしての脂質
WO2018067822A1 (en) * 2016-10-05 2018-04-12 Pds Biotechnology Corporation Methods to alter the tumor microenvironment for effective cancer immunotherapy
US10874733B2 (en) * 2016-10-31 2020-12-29 Eyegene Inc. Composition for enhancing immunity comprising immune modulator and cationic liposome, and use of same
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
CN111655238A (zh) 2017-12-05 2020-09-11 Pds生物科技公司 用于刺激i型干扰素基因的包括阳离子脂质的方法和组合物
JP7813226B2 (ja) * 2019-11-18 2026-02-12 ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン がん免疫療法のために常在型樹状細胞を超活性化する刺激
EP4247493A4 (en) * 2020-11-20 2024-10-09 PDS Biotechnology Corporation METHODS AND COMPOSITIONS CONTAINING CATIONIC LIPIDS FOR IMMUNOTHERAPY BY DIRECT TUMOR INJECTION
EP4604990A2 (en) * 2022-10-19 2025-08-27 PDS Biotechnology Corporation Novel t cell activating immunotherapeutic for treatment of mucin 1 protein expressing human cancers

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2167480A (en) 1927-11-02 1939-07-25 Rca Corp Signaling
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
JPS6440808A (en) 1987-08-05 1989-02-13 Canon Kk Zoom lens
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6183745B1 (en) 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
WO1993003709A1 (en) 1991-08-16 1993-03-04 Vical, Inc. Composition and method for treating cystic fibrosis
JP3738395B2 (ja) 1991-08-26 2006-01-25 エピミューン，インコーポレイティド Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US7105574B1 (en) 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
AU702517B2 (en) 1993-08-06 1999-02-25 Epimmune, Inc. Cloning and characterization of the complete MAGE-1 gene
AUPM500494A0 (en) 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
FR2732895B1 (fr) 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
EP0840622A4 (en) 1995-07-21 2003-01-02 Aventis Pharma Inc ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY
JP2001503735A (ja) 1996-07-03 2001-03-21 ユニバーシティ オブ ピッツバーグ 親水性活性試薬のためのエマルジョン処方物
US7001614B2 (en) 1996-08-19 2006-02-21 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US7288266B2 (en) 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
US20030229040A1 (en) 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
EP1146907A2 (en) 1999-02-05 2001-10-24 Genzyme Corporation Use of cationic lipids to generate anti-tumor immunity
CA2363141C (en) 1999-02-26 2010-04-06 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
JP4800485B2 (ja) 1999-03-26 2011-10-26 バイカル インコーポレイテッド ポリヌクレオチドベースのワクチンに対する免疫応答を増強するためのアジュバント組成物および方法
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
JP5117648B2 (ja) 1999-04-20 2013-01-16 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア カチオン性ｐｅｇ脂質および使用方法。
US6649170B1 (en) 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
EP1185662B1 (fr) 1999-06-10 2011-03-02 Merial Vaccins adn pour les chiens
CA2309313A1 (en) 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
EP1214097B3 (en) 1999-09-16 2011-07-20 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
US20030008813A1 (en) 1999-12-17 2003-01-09 Felgner Philip L. Intracellular protein delivery compositions and methods of use
US20010026937A1 (en) 2000-01-11 2001-10-04 Juha Punnonen Monocyte-derived dendritic cell subsets
EP1257565A4 (en) * 2000-02-01 2005-04-06 Austin Research Inst DERIVED FROM MUCIN-1 ANTIGENE AND ITS USE IN IMMUNOTHERAPY
WO2001080900A2 (en) 2000-04-20 2001-11-01 The University Of British Columbia Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
AU2001297693A1 (en) 2000-12-08 2002-09-12 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
EP1355628A2 (en) 2001-02-01 2003-10-29 Board of Regents, The University of Texas System Stabilised polymeric aerosols for pulmonary gene delivery
WO2002077012A2 (en) 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
FR2824326B1 (fr) 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
US7025987B2 (en) * 2001-05-30 2006-04-11 The Scripps Research Institute Delivery system for nucleic acids
NZ530635A (en) * 2001-06-15 2007-03-30 Nordic Vaccine Technology As Therapeutical vaccination comprising an immunogen and a targeting vehicle comprising a carrier and a antigen silmilar to the first
CA2451846A1 (en) 2001-06-29 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine comprizing a cancer antigen based on the product of a tumor suppressor gene wt1 and a cationic liposome
JP2004534088A (ja) * 2001-07-06 2004-11-11 スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ 癌のための多価コンジュゲートワクチン
GB0118517D0 (en) 2001-07-30 2001-09-19 Mitsubishi Tokyo Pharm Inc Compound
DE60238864D1 (de) 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
US7598421B2 (en) 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
AU2003244855A1 (en) 2002-07-05 2004-01-23 Lipoxen Technologies Limited Method to enhance an immune response of nucleic acid vaccination
WO2004014957A1 (en) 2002-08-12 2004-02-19 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes
US20050031587A1 (en) 2002-10-04 2005-02-10 Yamanouchi Pharmaceutical Co., Ltd. Immune response induction method
AU2003284239B2 (en) 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
SE0301109D0 (sv) 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
JP2007500239A (ja) 2003-05-30 2007-01-11 アルザ・コーポレーシヨン 薬剤の肺投与の方法
WO2005000889A1 (en) 2003-06-05 2005-01-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides for the treatment of prostate and breast cancer
US7906122B2 (en) 2003-06-18 2011-03-15 Yissum Research Development Company Of The Hebrew University Of Jersusalem Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
US8242089B2 (en) 2003-06-18 2012-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids polyalkylamine conjugates for use in transfection
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005014110A1 (en) 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
JP5097400B2 (ja) 2003-09-03 2012-12-12 デンドリセラピューティクス、インク． 複合ワクチン
US20050112559A1 (en) * 2003-09-29 2005-05-26 The Chinese University Of Hong Kong Compositions and methods for diagnosing and preventing severe acute respiratory syndrome (SARS)
SG133594A1 (en) 2003-12-10 2007-07-30 Canji Inc Methods and compositions for treatment of interferon-resistant tumors
CN1559607A (zh) 2004-02-20 2005-01-05 �й�ũҵ��ѧ 一种核酸物质与蛋白质类组合物及其生产方法和在免疫调节中的应用
WO2005097181A1 (en) 2004-04-05 2005-10-20 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
EP1781593B1 (en) 2004-06-07 2011-12-14 Protiva Biotherapeutics Inc. Cationic lipids and methods of use
KR20070052273A (ko) * 2004-06-30 2007-05-21 아이디 바이오메디컬 코포레이션 오브 퀘벡 코로나바이러스 감염의 치료를 위한 백신 조성물
US20060051405A1 (en) 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
CA2589992C (en) 2004-12-13 2014-04-22 Peplin Research Pty Ltd Treatment of solid cancers
US20060159738A1 (en) * 2004-12-14 2006-07-20 Applera Corporation Cationic liposomes and methods of use
KR20080012825A (ko) 2005-01-21 2008-02-12 인트로겐 테라페티스, 인코퍼레이티드 표적 세포가 치료적 및 예방적 핵산에 지속 노출되게 하는국소 투여
WO2007149062A2 (en) 2005-03-14 2007-12-27 Board Of Regents, The University Of Texas System Bioactive fus1 peptides and nanoprticle-polypeptide complexes
JP4516147B2 (ja) 2005-03-18 2010-08-04 ヴェーデクス・アクティーセルスカプ 補聴器用遠隔制御システム
EP1882031B1 (en) 2005-04-08 2017-11-08 Argos Therapeutics, Inc. Dendritic cell compositions and methods
EP1877088B1 (en) 2005-04-11 2014-12-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccine against pandemic strains of influenza viruses
US20060275777A1 (en) 2005-06-03 2006-12-07 Waelti Ernst R Novel strategies for protein vaccines
WO2007022152A2 (en) 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
US20110305713A1 (en) 2005-10-21 2011-12-15 Medical College Of Georgia Research Institute, Inc Methods and compositions to enhance vaccine efficacy by reprogramming regulatory t cells
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
US8802419B2 (en) * 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
JP2007238559A (ja) 2006-03-10 2007-09-20 Nagoya City Univ 未成熟樹状細胞活性化剤及びその使用
EP2013230A2 (en) 2006-04-21 2009-01-14 Transgene S.A. Hpv-16-based papillomavirus vaccine
US20080014251A1 (en) 2006-07-14 2008-01-17 Advanced Vascular Dynamics Hemostatic compound and its use
EP1894941A1 (en) 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US20100099745A1 (en) 2006-10-18 2010-04-22 Suryaprakash Sambhara Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors
KR100817024B1 (ko) 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2688346A1 (en) 2007-05-23 2008-12-04 Vical Incorporated Compositions and methods for enhancing immune responses to vaccines
US7832751B2 (en) * 2007-06-29 2010-11-16 Harley-Davidson Motor Company Group, Inc. Rear fender assembly
JP5623910B2 (ja) 2007-11-02 2014-11-12 ザ ジョンズ ホプキンス ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ ヒトパピローマウイルス感染症の治療又は予防のための複数型ｈｐｖペプチド組成物及び方法
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2009142892A1 (en) 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
US20100086584A1 (en) 2008-09-18 2010-04-08 Juvaris Biotherapeutics, Inc. VACCINE COMPOSITIONS OF M2e, HA0 AND BM2 MULTIPLE ANTIGENIC PEPTIDES
CA2754826A1 (en) 2009-03-06 2010-09-10 Mount Sinai School Of Medicine Live attenuated influenza virus vaccines comprising microrna response elements
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
WO2011109294A1 (en) 2010-03-01 2011-09-09 Dicerna Pharmaceuticals, Inc. Lipid delivery formulations
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
US9408914B2 (en) 2010-04-28 2016-08-09 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
AR087380A1 (es) 2011-07-27 2014-03-19 Baylor Res Inst Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas
ES2689799T3 (es) 2011-09-12 2018-11-15 Pds Biotechnology Corporation Formulaciones de vacunas particuladas
EP2638896A1 (en) 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
AU2013274235B2 (en) 2012-06-15 2018-01-18 Samir N. Khleif Cationic lipid vaccine compositions and methods of use
AU2013317805B2 (en) 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
SG11201510748PA (en) 2013-08-21 2016-03-30 Curevac Ag Composition and vaccine for treating lung cancer
AU2014340201B2 (en) 2013-10-23 2019-02-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
CN104189897A (zh) 2014-05-21 2014-12-10 深圳先进技术研究院 一种树突状细胞高效负载抗原的制备方法
KR102668219B1 (ko) 2015-03-16 2024-05-28 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Mhc 세포 라이브러리를 이용하여 신규한 면역원성 t 세포 에피토프를 검출하고 신규한 항원-특이적 t 세포 수용체를 단리하는 방법
CN105920599B (zh) 2015-09-17 2020-02-11 武汉生物制品研究所有限责任公司 以阳离子脂质体dotap为佐剂的疫苗及其制备方法
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
WO2018067822A1 (en) 2016-10-05 2018-04-12 Pds Biotechnology Corporation Methods to alter the tumor microenvironment for effective cancer immunotherapy
JP7165652B2 (ja) 2016-10-05 2022-11-04 ピーディーエス バイオテクノロジー コーポレイション 新規ｈｐｖ１６非ｈｌａ拘束性ｔ細胞ワクチン、その組成物及び使用方法
CN111655238A (zh) 2017-12-05 2020-09-11 Pds生物科技公司 用于刺激i型干扰素基因的包括阳离子脂质的方法和组合物
CN111217918B (zh) * 2020-03-04 2020-11-10 中山大学 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗

Similar Documents

Publication Publication Date Title
JP2011518170A5 (enExample)
Reed et al. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants
ES2656696T3 (es) Compuestos heterocíclicos tricíclicos condensados como inhibidores de la integrasa del VIH
RU2018111327A (ru) Способ ингибирования всасывания и/или повышения выведения липидов с использованием d-псикозы
HRP20130023T1 (hr) Cjepivo koje sadrži emulziju ulje u vodi kao adjuvans
UY32599A (es) Formulación oral sólida de abt-263
HRP20221263T1 (hr) Ciklički di-nukleotidni spojevi i postupci uporabe
MX348705B (es) Composiciones farmacéuticas y métodos de administración relacionados.
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
DOP2009000239A (es) Vacuna de influenza de emulsion de aceite en agua
CA2816564A1 (en) Inflammatory disease
JP2015528471A5 (enExample)
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
JP2017524682A5 (enExample)
EA200701519A1 (ru) Живая аттенуированная ротавирусная вакцина для перорального введения
AR083361A1 (es) Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon
EP2812030A4 (en) COMBINED ANTIGEN AND DNA VACCINE FOR THE PREVENTION AND TREATMENT OF RSV INFECTIONS
JP2014515035A5 (enExample)
MX2011008923A (es) Composicion inmunogena.
MY157513A (en) A water-in-oil type emulsion for treating a disease of the eye
PH12014502836B1 (en) Medicament form for release of active ingredients
ES2361284T3 (es) Combinaciones terapéuticas.
JP2020536098A5 (enExample)
HRP20251123T1 (hr) Ekopipam za liječenje touretteovog sindroma
JP2008539169A5 (enExample)